Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q1 FY2013 Earnings Presentation
8 slides from Alembic Pharmaceuticals's earnings presentation, June 2012
Slide 1: Investors Update – Q1FY13
Alembic Pharmaceuticals Limited Investors Update – Q1FY13 Quarter ended 30th June, 2012 Net sales up 7% at Rs 368 crores for the quarter against Rs. 345 crores in corresponding quarter last year Domestic formulations sales up 14% for the quarter at Rs. 197 crores against Rs. 172 crores in corres
Slide 2: Management Discussion – Q1FY13
Management Discussion – Q1FY13 Alembic Pharmaceuticals Limited reported a 7% increase in revenues to Rs 368.06 crores for the quarter ended 30th June 2012, compared to Rs 344.72 crores in the corresponding quarter last year. The Company posted 7% growth in profit before tax at Rs. 38.09 crores for t
Slide 3: Therapy wise performance
Therapy wise performance: June - 2012 June - 2011 The company launched a dermatology division during the quarter with a field force of 100 people. This will further add to the basket of specialty products and growth in the future. ORG - June 12 JUN 12 MAT JUN 11 MAT Therapy Market Alembic Therapy Ma
Slide 4: International Generics
International Generics International Generic Formulation sales is Rs. 46.05 crores against Rs. 61.15 crores over the corresponding quarter last year. De-growth was in line with our expectations due to price erosion, product mix and capacity constraint. The Company is in the midst of a capacity exp
Slide 5: Europe and emerging markets focus; ANDA filing summary
The Company is also increasing its focus on Europe and emerging markets. It filed its first Brazilian Dossier with the ANVISA and filed 1 dossier each in Europe and Australia. In the quarter 1 USDMF was filed, which takes the total to 63 USDMF filings. ANDA Filing summary: FY07 FY08 FY09 FY10 FY11 F
Slide 6: Financial and Operating Result – Q1FY13
Interest Net Interest costs during the quarter was at Rs. 5.74 crores while for corresponding year it was Rs. 6.77 crores. Financial and Operating Result – Q1FY13 (Rs. Lacs) Particulars Q1FY13 Q1FY12 Income from Operations 36,677 34,367 Total Expenditure 31,450 29,332 - (Increase) / decrease in stoc
Slide 7: Summary of total revenue and profit break-up
Summary of total revenue (consolidated) for the quarter is as under: (Rs. in Lacs) Particulars Q1 FY13 Q1 FY12 % Change Formulation Domestic 19724 17244 14% International Branded 755 1132 (-)33% International Generics 4605 6115 (-)25% API Domestic 3047 3475 (-)12% International 8348 6073 37% Export
Slide 8: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharm
Alembic Pharmaceuticals — Q1 FY2013 Earnings Presentation on 6ix